New stock news | Qin Hao Pharmaceuticals submits application to Hong Kong Stock Exchange.

According to the disclosure on January 16th by the Hong Kong Stock Exchange, QuintaMed Pharmaceuticals (Suzhou) Co., Ltd.-B (referred to as QuintaMed Pharmaceuticals) submitted its application for listing on the main board of the Hong Kong Stock Exchange, with Huatai International as its exclusive sponsor. According to the prospectus, as of January 7, 2026, the company's pipeline includes seven independently developed candidate drugs, including four in clinical stage, one approved by the Chinese National Medical Products Administration and the US FDA for IND, and two in preclinical stage. The company is a biopharmaceutical company with a differentiated and powerful pipeline of innovative candidate drugs developed independently around the RAS signaling pathway and synthetic lethality mechanism. According to data from Zhoushi Consultancy, in terms of clinical progress targeting the same target, the company's multiple candidate drugs are in a leading position globally. The company mainly focuses on developing potential best-in-class targeted therapies in the field of oncology. Since its establishment in 2014, the company has been using its expertise and insights accumulated in translational medicine to drive continuous innovation.